SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs admitted affair with a business executive accused of ties to Chinese intelligence, and Nvidias board investigation, are weighing on shares and raising concerns about leadership and possible security disclosures. Traders disagree over whether the controversy poses a lasting risk or is a short-term overreaction, with many viewing the selloff as a buying opportunity because Nvidias business remains strong.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims is drawing attention as shares sell off ahead of its Q3 earnings report, prompting unverified speculation among traders about an earnings leak. The community is divided on the outlook, with optimism about growth and the Lilly weight-loss-drug partnership set against concerns that branded GLP-1 sales could pressure margins and guidance.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A sharp pre-earnings rally has put TTD in focus, with traders attributing the move to possible short covering and speculating about an earnings leakneither is confirmed. The community is split between hopes for a turnaround and concerns that weak growth or guidance could reverse the gains.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs sharp rebound is being framed by traders as a rotation from Nvidia amid the Jensen Huang board-probe headlines, with some debating whether that shift will translate into lasting business gains. An Oppenheimer upgrade and Google Clouds use of AMD EPYC processors in its AI infrastructure are also cited as company-specific support, alongside optimism about data-center demand.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeings earnings update and management commentary on a slower 737 MAX production ramp and delayed cash-flow recovery have driven a sharp selloff and analyst estimate cuts. Traders are divided between viewing the drop as an oversold opportunity backed by Boeings backlog and defense business, and seeing continued execution and cash-flow risks as reasons for further weakness.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs preliminary third-quarter results, which traders viewed as a strong revenue beat, and Brad Jacobs upbeat business update have fueled a sharp rally. Bulls are cheering the volume surge and speculating about short covering, while some remain cautious about acquisition integration and dilution.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clovers Q3 earnings beat and improved full-year outlook, alongside continued profitability and Medicare Advantage growth, are fueling discussion. Bulls view the results as evidence of improving fundamentals, while skeptics point to the lack of concrete Counterpart SaaS revenue details and debate whether the shares can hold above a key price level.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.11892236 USD and is down -3.62 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,884,610,999.15 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is drawing attention amid a sharp crypto-wide selloff, with Bitcoin weakness and reported liquidations adding pressure as traders watch whether XRP will fall below $1. The community is split between treating the decline as a buying opportunity and expecting further losses, with some attributing the weakness to political and regulatory uncertainty.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

A stronger-than-expected third-quarter earnings report and raised 2026 outlook are driving CEGs attention. Traders are reacting positively to the results, with some also pointing to long-term nuclear power demand from data centers as a growth tailwind.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lillys Hims & Hers deal to make Zepbound and Foundayo available through the telehealth platform has traders focused on broader access to its obesity drugs; the community sees a potential boost to reach but debates competition and how much demand the channel will generate. Positive Phase 3 sleep-apnea results for Foundayo are also adding to optimism about Lillys oral obesity franchise.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Helus Pharma is drawing attention ahead of expected Q4 2026 Phase 3 APPROACH topline results for HLP003, its investigational depression treatment. Bulls emphasize its adjunctive trial design and potential for shorter clinic visits, while skeptics point to binary trial risk, possible dilution, and competition in psychedelic therapies.

CMPS, HELP Stocks On Track For Worst Day In Months On Competitive FDA Psychedelic Race Fears

Equity

According to a report from Psychedelic Alpha, Usona has finished submitting its application for psilocybin in major depressive disorder, making it the second psychedelic under review by the agency at present.


Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?

Cybin Inc. (HELP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.


Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Inspire Medical, Cybin and Aveanna show overbought RSI readings above 70, signaling potential momentum warnings for healthcare investors.read more...

HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62  

TD Cowen lifted its target on HELP to $62 from $8 on Thursday, while maintaining a Buy rating.


Helus Pharma Appoints Michael Halstead CEO, Effective Immediately

(RTTNews) - On Monday, Cybin D/B/A Helus Pharma (HELP) announced that it has appointed Michael Halstead as Chief Executive Officer, effective immediately...

CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.


HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs 

Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.


A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire NEW YORK and TORONTO, July 21, 2026 Issued on behalf of...

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates PR Newswire NEW YORK, July 21, 2026 Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations...

Helus Pharma Inc.

3rd Annual Guggenheim Healthcare Innovation Conference

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Bullish Sentiment

<ul class="summary-bullets"><li>Compass is developing COMP360, a proprietary synthetic psilocybin, specifically for treatment-resistant depression.</li><li>The company has previously said that it expects to complete its full submission to the FDA for the drug in the fourth quarter of 2026.&nbsp;</li><li>Compass is slated to report its third-quarter earnings on Tuesday, when management is expected to provide further updates on its regulatory timeline.</li></ul>Shares of Compass Pathways (CMPS) fell 28% on Monday after rival and non-profit research organization Usona Institute reportedly completed its application to the U.S. Food and Drug Administration for a psilocybin treatment in major depressive disorder.The stock is now on track for its worst day since June 2025, if the losses hold.<h2 class="st-heading-2">Rival Application Pressures CMPS, HELP</h2>According to a report from Psychedelic Alpha, Usona has finished submitting its application for psilocybin in major depressive disorder, making it the second psychedelic under review by the agency at present. Usona, like Compass Pathways, has a Commissioner's National Priority Voucher which is designed to support an accelerated review potentially lasting one to two months after acceptance.Compass, meanwhile, is developing COMP360, a proprietary synthetic psilocybin, specifically for treatment-resistant depression. The company has two positive late-stage trials, a rolling NDA already underway, and has guided that it expects to complete its full submission in the fourth quarter of 2026, with a potential commercial launch in the first half of 2027, subject to FDA approval and Drug Enforcement Administration (DEA) rescheduling for psychedelic drugs.Compass is slated to report its third-quarter earnings on Tuesday, when management is expected to provide further updates on its regulatory timeline. According to data from Fiscal AI, Wall Street on average expects the company to report a loss per share of $0.41.In addition, shares of Helus Pharma fell sharply by 18% on Usona’s application news, on track for its worst day since March 2026. Helus is developing its own psychedelic-based HLP003 as an adjunctive treatment for MDD; the company expects to file an application for the drug’s approval in 2028.<h2 class="st-heading-2">How Did CMPS Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$CMPS" data-symbol-id="CMPS" href="https://stocktwits.com/symbol/CMPS" target="_blank">CMPS stock</a> jumped from 'neutral' to 'bullish' territory over the past 24 hours, while message volume stayed at 'high' levels.A Stocktwits user dismissed the selloff, noting that the Usna competition has been known for years and expressed optimism for positive updates on the company’s earnings call.<stembedurl>https://stocktwits.com/ROCKYGEM711/message/667936902</stembedurl>Another user opined that the stock is entering “make or break season.”<stembedurl>https://stocktwits.com/Dazza933/message/667915612</stembedurl>CMPS stock has gained 19% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/black-cautions-tesla-shareholders-on-space-x-merger-risks-says-marvell-lumentum-deal-reaction-offers-early-warning/cNGa3WER9Po">Gary Black Cautions Tesla Shareholders On SpaceX Merger Risks: Says Marvell-Lumentum Deal Reaction Offers Early Warning</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

According to a report from Psychedelic Alpha, Usona has finished submitting its application for psilocybin in major depressive disorder, making it the second psychedelic under review by the agency at present.

COMPASS Pathways

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$9.34
Prev Close	$8.96
Open	$9.23
Dividend Yield	N/A
50-Day Moving Average	$11.51
Beta	1.15
Avg. Volume	1.45M
PE Ratio	-2.11

52-Week High	$15.15
52-Week Low	$3.76
Market Capitalization	$654.62M
EPS (Annual)	-$4.25
Price to Book	2.29
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

HELP Fundamentals